Find research datasets worth reusing
Search datasets from major research repositories and use ShareScore to quickly assess how well each record supports discovery, access, and reuse.
376
datasets available to search
ShareScore release 0.9.0
Dataset results
376 results for “SARS-CoV-2 vaccine”
A Study of mRNA-based Influenza and SARS-CoV-2 (COVID-19) Multi-component Vaccines in Healthy Adults
ClinicalTrials.gov study NCT05827926. IPD Sharing: Not stated. Countries: 1. Publications: 1.
Safety and Immunogenicity Study of a SARS-CoV-2 (COVID-19) Variant Vaccine (mRNA-1273.351) in Naïve and Previously Vaccinated Adults
ClinicalTrials.gov study NCT04785144. IPD Sharing: Not stated. Countries: 1. Publications: 1.
A Study to Evaluate the Immunogenicity and Safety of mRNA Vaccine Boosters for SARS-CoV-2 (COVID-19) Variants
ClinicalTrials.gov study NCT04927065. IPD Sharing: Not stated. Countries: 1. Publications: 3.
A Phase 2b/3, Randomized, Observer-Blinded, Placebo-Controlled, Multicenter Clinical Study Evaluating the Efficacy and Safety of Investigational SARS-CoV-2 mRNA Vaccine CVnCoV in Adults 18 Years of Ag
ClinicalTrials.gov study NCT04652102. IPD Sharing: Not stated. Countries: 10. Publications: 1.
A Phase-I Study of a Nanoparticle-based Peptide Vaccine Against SARS-CoV-2
ClinicalTrials.gov study NCT05113862. IPD Sharing: YES. Countries: 1. Publications: 1.
Safety and Immunogenicity Study of 2019-nCoV Vaccine (mRNA-1273) for Prophylaxis of SARS-CoV-2 Infection (COVID-19)
ClinicalTrials.gov study NCT04283461. IPD Sharing: Not stated. Countries: 1. Publications: 8.
Phase II Study of AVX/COVID-12 Vaccine in Subjects With Prior SARS-CoV-2 Immunity Evidence
ClinicalTrials.gov study NCT05205746. IPD Sharing: YES. Countries: 1. Publications: 57.
Pregnancy and lactation induce distinct immune responses to COVID-19 booster vaccination and SARS-CoV-2 breakthrough infection
Open the record for dataset details and reuse information.
Data for: Oligonucleotide mapping via mass spectrometry to enable comprehensive primary structure characterization of an mRNA vaccine against SARS-CoV-2
Open the record for dataset details and reuse information.
Effectiveness of Inactivated SARS-CoV-2 Vaccine (CoronaVac) on Survival at Intensive Care Unit: A Cross-sectional Study
<p><em>Background: </em>This study compared the course of COVID-19 in vaccinated and unvaccinated patients admitted to an intensive care unit (ICU) and evaluated the effect of vaccination with CoronaVac on admission to ICU.</p> <p><em>Methods: </em>Patients admitted to ICU due to COVID-19 between 1 April 2021 and 15 May 2021 were enrolled to the study. Clinical, laboratory, radiological parameters, hospital and intensive care unit mortality were compared between vaccinated patients and eligible but unvaccinated patients. Patients over 65 years old were the target population of the study due to the national vaccination schedule.</p> <p><em>Results: </em>Data from 90 patients were evaluated. Of these, 36 (40.0%) were vaccinated. All patients had the CoronaVac vaccine. Lactate dehydrogenase and ferritin levels were higher in unvaccinated group than vaccinated group (p=0.021 and 0.008, respectively). SpO<sub>2</sub> from the first arterial blood gas at ICU was 83.71±19.50 % in vaccinated, 92.36±6.59 % in unvaccinated patients (p=0.003). Length of ICU and hospital stay were not different (p=0.204, 0.092, respectively). ICU and hospital mortality were similar between groups <strong>(<strong>p=0.11 and 0.70, respectively</strong>).</strong></p> <p><em>Conclusions: </em>CoronaVac vaccine had no effect on survival from COVID-19. CoronaVac’s protective effect, especially on new genetic variants, should be investigated further.</p>
Serial seroprevalence study: follow-up of immunity to SARS-Cov-2 infection and monitoring of effective vaccination coverage, in three Chilean cities
<p>Population-based serosurvey in Santiago, Talca, and Coquimbo–La Serena </p>
Neutralizing immunity in vaccine breakthrough infections from the SARS-CoV-2 Omicron and Delta variants
<p>Scripts and metadata used in the analysis of the manuscript, <em>Neutralizing immunity in vaccine breakthrough infections from the SARS-CoV-2 Omicron and Delta variants.</em></p>
Dataset for "Glycaemic control is associated with SARS-CoV-2 breakthrough infections in vaccinated patients with Type 2 diabetes"
<p>Dataset for "Glycaemic control is associated with SARS-CoV-2 breakthrough infections in vaccinated patients with Type 2 diabetes"</p>
Safety and immunogenicity of heterologous booster immunization with Ad5-nCoV after three-dose priming with inactivated SARS-CoV-2 vaccine in Chinese adults: a randomized, double-blind, parallel-controlled trial
<p>Data on safety and immunity of heterologous booster (fourth dose) after three-dose priming with inactivated SARS-CoV-2 vaccine are limited in Chinese adults. Here, we evaluate the safety and immunogenicity of immunization with Ad5-nCoV in a randomized, double-blind, parallel-controlled phase 4 clinical trial in Zhejiang, China (NCT05373030). Participants aged 18-80 years (100 participants per group) who have administered three doses of inactivated SARS-CoV-2 vaccine ≥ 6-month earlier were enrolled and randomized at 1:1 into two groups, then administered intramuscular Ad5-nCoV or different inactivated SARS-CoV-2 vaccine (CoronaVac or Covilo) respectively. All observed adverse reactions were predictable and manageable. Ad5-nCoV elicited significantly higher RBD-specific IgG levels, with a GMC of 2924.0 on day 14 post-booster, 7.8-fold that of the inactivated vaccine. Pseudovirus-neutralizing antibodies to Omicron BA.4/5 showed a similar pattern, with GMT of 228.9 in the Ad5-nCoV group and 65.5 in the inactivated vaccine group. The Ad5-nCoV booster-maintained a high antibody levels on day 90, with seroconversion of 71.4%, while the inactivated vaccine group was 5.2%, closed to pre-booster levels. In summary, a fourth Ad5-nCoV vaccination following three-dose inactivated SARS-CoV-2 vaccination is immunogenic, tolerable, and more efficient than inactivated SARS-CoV-2 vaccine. Ad5-nCoV elicits a stronger humoral response against Omicron BA.4/5 and maintains antibody levels for longer than homologous boosting.</p>
Codes and datasets for: Quantifying the impact of SARS-CoV-2 temporal vaccination trends and disparities on disease control
<p>Codes and datasets to reproduce the main figures of the article titled: "Quantifying the impact of SARS-CoV-2 temporal vaccination trends and disparities on disease control".</p>
CD4+ and CD8+ T cell responses to peptides covering SARS-CoV-2 Spike in response to mRNA vaccination in persons recovered from SARS-CoV-2 infection
<p>These files contain intracellular cytokine staining flow cytometry data for CD4+ and CD8+ T cells after exposure of serial PBMC to SARS-CoV-2 spike peptides or control antigens. PBMC are from subjects recovered from SARS-CoV-2 infection that subsequently received mRNA vaccination. The data were analyzed and exported from FlowJo version 10 as individual gated events and related Boolean subsets for four functional markers: CD40L, IFN-g, IL-2, and TNF-a. Counts and frequencies are both included.</p> <p> </p> <p><strong>Procedure for obtaining data:</strong></p> <p>Cryopreserved peripheral blood mononuclear cells (PBMC) were thawed and rested overnight. PBMC (1 x 10<sup>6</sup> per well) were stimulated with a SARS-CoV-2 spike overlapping peptide pool (JPT, 1 μg/mL each peptide; 0.4% final DMSO concentration), 0.4% DMSO as a negative control, or PHA-P (Remel; 1.6 μg/mL final concentration) as a positive control, in the presence of anti-CD28 and anti-CD49d (BD Biosciences) antibodies at 37°C for 6 hours. Brefeldin A (Sigma) was added after 2 hours. Cells were stained with Live/Dead Near IR dye (Invitrogen), treated with FACS lyse (BD Biosciences) and frozen at -80<sup>o</sup>C. For staining, the cells were thawed, washed, and permeabilized with Permeabilizing solution 2 (BD Biosciences) then stained with fluorochrome labeled monoclonal antibodies to anti-human CD3 mAb (clone UCHT) conjugated with PE-Texas Red (ECD; Beckman Coulter), anti-human CD4 mAb (clone SK3) conjugated with BV510 (Biolegend), anti-human CD8 mAb (clone SK1) conjugated with PerCP-Cy5.5 (BD Biosciences), and the activation markers anti-human CD40L mAb (clone TRAP1) conjugated with BV421 (BD Biosciences), anti-human IFNγ mAb (clone 4S.B3) conjugated with PE (BD Biosciences), anti-human IL2 mAb (clone MQ1-17H12) conjugated with APC (BD Biosciences), and anti-human TNFα mAb (clone MAb11) conjugated with FITC (BD Biosciences). Events were recorded with BD Fortessa and analyzed with FlowJo (v10 for Mac; BD). </p>
Longitudinal Assessment of TCR Repertoires in Recipients of Inactivated SARS-CoV-2 Vaccines: An Artificial Intelligence-Guided Study
<p>T cells play a crucial role in mitigating disease severity during SARS-CoV-2 infection and in shaping long-term immune memory. However, the precise molecular immune response involving T-cell receptor (TCR) repertoire changes following full vaccination, and evaluating vaccine efficacy through TCR analysis, remains incompletely understood. In this study, we conducted a 10-month longitudinal investigation of individuals who received SARS-CoV-2 inactivated vaccines and developed a vaccine efficacy evaluation model. Through the advanced large language artificial intelligence method, we identified vaccine-specific TCR clones, 3 V genes, 20 V-J combinations, and 3 epitopes, and traced their longitudinal development. The vaccine-specific TCR clones expanded to peak levels after the second vaccine dose and remained detectable in most subjects at 10 months. Utilizing vaccine-specific TCRs as novel markers, we constructed a vaccine efficacy evaluation model that predicts antibody levels with a mean AUC of 0.96, highlighting the relationship between vaccine-specific TCRs and antibodies. Our findings reveal the longitudinal patterns of vaccine-specific TCR clones and the potential of the efficacy evaluation model built upon them.</p>
Study of a Severe Acute Respiratory Syndrome CoV-2 (SARS-CoV-2) Virus-like Particle (VLP) Vaccine in Healthy Adults
ClinicalTrials.gov study NCT04818281. IPD Sharing: Not stated. Countries: 1. Publications: 1.
Safety and Immunogenicity Trial of an Oral SARS-CoV-2 Vaccine (VXA-CoV2-1) for Prevention of COVID-19 in Healthy Adults and Boost (VXA-CoV2-1.1-S) at 1 Year Post Initial Vaccination in Subset of Subje
ClinicalTrials.gov study NCT04563702. IPD Sharing: UNDECIDED. Countries: 1. Publications: 1.
Influences of Allergic Rhinitis and Allergen Immunotherapy on SARS-CoV-2 Vaccination
ClinicalTrials.gov study NCT05009134. IPD Sharing: NO. Countries: 1. Publications: 2.
ScienceDex guides
Understand access before you commit
These curated guides explain access requirements, typical timelines, costs, and reuse considerations for widely used research datasets.
Allen Brain Atlas
Allen Brain Atlas is an Allen Institute collection of brain map atlases, datasets, APIs, and analysis tools covering mouse, human, and non-human primate brain resources.
Annotated Behaviour and Observability Dataset (ABODe)
ABODe is a University of Edinburgh DataShare dataset for behavior classification in group-housed mice using home-cage video, identities, bounding boxes, ground-plate positions, and annotator labels.
DANDI Archive for NWB datasets
DANDI is a BRAIN Initiative archive for publishing and sharing neurophysiology data, including electrophysiology, optophysiology, and behavioral data packaged as NWB and related standards.
International Brain Laboratory public data
The International Brain Laboratory public data releases expose standardized mouse decision-making experiments, including Neuropixels recordings, widefield calcium imaging, behavior, and session metadata accessed through the ONE API.
OpenNeuro
OpenNeuro is a free, open platform for sharing neuroimaging datasets, with public search, dataset pages, and download paths for web, S3, DataLad, and the OpenNeuro CLI.